The evolution in melanoma treatment as a reflection of precision-oriented medicine (Review)

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 424-426

  Kushnir, Igal ^a   Merimsky, Ofer ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

BRAF inhibitor; Melanoma; Precision medicine; Treatment

Indexed keywords

BLEOMYCIN; CARMUSTINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ERLOTINIB; FLUOROURACIL; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; LOMUSTINE; MERCAPTOPURINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOMYCIN; PEPTIDE VACCINE; TAMOXIFEN; TRASTUZUMAB; VEMURAFENIB; VINBLASTINE;

CANCER IMMUNOTHERAPY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE;

EID: 84871581221     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1065     Document Type: Review

References (21)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Hayat MJ, Howlader N, Reichman ME and Edwards BK: Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12: 20-37, 2007.
3. Luce JK: Chemotherapy of malignant melanoma. Cancer 30: 1604-1615, 1972.
4. Benjamin RS: Chemotherapy of malignant melanoma. World J Surg 3: 321-328, 1979.
5. Huncharek M, Caubet JF and McGarry R: Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11: 75-81, 2001.
6. Legha SS, Ring S, Papadopoulos N, Plager C and Benjamin R: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64: 2024-2029, 1989.
7. Atkins MB, Hsu J, Lee S, et al: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26: 5748-5754, 2008.
8. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol17: 2745-2751, 1999.
9. Lewis MG: Possible immunological factors in human malignant melanoma in Uganda. Lancet 2: 921-922, 1967.
10. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW and McCarthy WH: Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Inves Dermatol 97: 197-202, 1991.
11. Ram M and Shoenfeld Y: Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci 1110: 410-425, 2007.
12. Merimsky O, Shoenfeld Y and Fishman P: The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions. Clin Rev Allergy Immunol 16: 227-236, 1998.
13. Fishman P, Azizi E, Shoenfeld Y, et al: Vitiligo autoantibodies are effective against melanoma. Cancer 72: 2365-2369, 1993.
14. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116, 1999.
15. Komenaka I, Hoerig H and Kaufman HL: Immunotherapy for melanoma. Clin Dermatol 22: 251-265, 2004.
16. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl JMed363: 711-723, 2010.
17. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
18. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714, 2012.
19. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
20. Curtin JA, Busam K, Pinkel D and Bastian BC: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340-4346, 2006.
21. Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26: 2046-2051, 2008.